PATENT CLAIM ANALYSIS

Application Number: 15992567
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "130100"]

Abstract:
The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-α) and soluble tumor necrosis factor-α receptor 1 (sTNFR1), and may further include testing for prostate serum antigen (PSA). Use of these markers in combination provides tests that are more sensitive and specific than PSA in differentiating benign versus malignant prostate disease and/or localized CaP versus metastatic CaP and show that the specificity and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by measuring IL-8, TNF-α and sTNFR1.

Claim (Index 2):
The kit of  claim 1 , wherein the capture antibodies are fixed to a substrate.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.48718
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14911580', '15304473', '13984669', '14781839', '14375535']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.672290256059031
- 35 USC 102 Novelty (BERT): 0.5271161753519409
- Combined Prediction Score: 0.657772847988322
- Mean Citation Score: 187.773928
- Max Citation Score: 304.86002
- Similarity Product: 210.24578580660344

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test